Philippe Ciais

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Retrieved on: 
Wednesday, October 11, 2023
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Nursing care plan, FCCP, Philippe Ciais, Food, Doctor of Philosophy, Division, Multidrug-resistant bacteria, Development, MD, Synergy, Infection, Meropenem, Therapy, Sulbactam, Combination, Food and Drug Administration, Fungal infection, Cefepime, Pseudomonas aeruginosa, FIDSA, Doctor of Pharmacy, Hartford Hospital, Research, Pharmaceutical industry, Vaccine, Antibiotics, Imipenem, Enterobacterales

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today plans to present an oral abstract and four poster sessions from their portfolio of U.S. Food and Drug Administration (FDA)-approved critical care and infectious disease therapies at IDWeek 2023, October 11-15, held in Boston, MA.

Key Points: 
  • Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today plans to present an oral abstract and four poster sessions from their portfolio of U.S. Food and Drug Administration (FDA)-approved critical care and infectious disease therapies at IDWeek 2023, October 11-15, held in Boston, MA.
  • XACDURO is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
  • In addition, four company-sponsored research studies on XACDURO will also be presented by the company’s research partners in poster sessions.
  • “Antibiotic-resistant pathogens are one of the most significant and challenging threats to healthcare providers on the frontlines of infectious disease care,” said Margaret Koziel, MD, Chief Medical Officer, Innoviva Specialty Therapeutics.

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

Retrieved on: 
Wednesday, October 19, 2022
Doctor of Pharmacy, GSK, PDR, Mortality, Infectious Diseases Society of America, Institute, II, Test, XDR, ELF, Poster, Infection, Philippe Ciais, Therapy, Septic, Blood pressure, Private Securities Litigation Reform Act, Company, Medical microbiology, Incidence, GLOBE, Clinical trial, Colistin, Fluticasone furoate/umeclidinium bromide/vilanterol, Population, Diversified Specialty Institute Holdings, Inc., Probability, Multidrug-resistant bacteria, PTA, Multiplicity of infection, Special access program, United, Authorization, Nephrotoxicity, Data analysis, PPK, Angiotensin, Note, SEC, ABC, Patient, Distributive shock, Nasdaq, Sulbactam, Acquisition, MD, Doctor of Philosophy, BLI, Safety, Plasma, Forward-looking statement, Gram, Pharmaceutical industry, Vaccine, Risk management, Antibiotics, Pseudomonas, Entasis, FIDSA

Results showed that ABC isolates from patients in ATTACK were highly antibiotic-resistant, but >95% susceptible to SUL-DUR.

Key Points: 
  • Results showed that ABC isolates from patients in ATTACK were highly antibiotic-resistant, but >95% susceptible to SUL-DUR.
  • This study evaluated PPK in 373 subjects, including 110 patients who received SUL-DUR and underwent PK sampling in the pivotal Phase 3 ATTACK trial.
  • In addition to the oral presentations, three poster presentations highlighted additional SUL-DUR and ATTACK trial details and results.
  • All Entasis IDWeek 2022 presentations will be made available on the Entasis website https://www.entasistx.com/our-science/presentations-by-event.

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022

Retrieved on: 
Wednesday, October 12, 2022
Angiotensin, Infection, Philippe Ciais, GSK, Note, SEC, Therapy, Septic, Fluticasone furoate/umeclidinium bromide/vilanterol, ABC, Patient, Kirkbi AG v Ritvik Holdings Inc, Blood pressure, Distributive shock, Infectious Diseases Society of America, Entasis, Nasdaq, II, Private Securities Litigation Reform Act, Company, Multidrug-resistant bacteria, Acquisition, Multiplicity of infection, United, 2021 Essex County Council election, GLOBE, Forward-looking statement, Gram, Pharmaceutical industry, Pseudomonas

Innoviva is a diversified holding company with a portfolio of royalties and innovative healthcare investments and assets.

Key Points: 
  • Innoviva is a diversified holding company with a portfolio of royalties and innovative healthcare investments and assets.
  • Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA.
  • Forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date hereof.
  • Trademark reference:Innovivaand theInnovivalogo are registered trademarks or trademarks ofInnoviva, Inc.or its affiliates inthe United Statesand/or other countries.

LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC

Retrieved on: 
Thursday, October 6, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Constellation, Philippe Ciais, Gemstone, Doctor of Philosophy, Therapy, Computer, Head, Cambridge Crystallographic Data Centre, ChemMedChem, Cell engineering, Multiple myeloma, Bortezomib, Patient, Pharmacy, CMC, Computational chemistry, Drug discovery, Multiplicity of infection, Negotiation, Harvard University, Journal, University of Freiburg, Medicinal chemistry, University, Biophysics, Journal of Medicinal Chemistry, Data science, Biochemistry, Fine chemical, Pharmaceutical industry, MorphoSys, Chemistry

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.

Key Points: 
  • LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.
  • Dr. Stahl, former global head of lead discovery at Roche, will also lead LifeMines operations at its European offices in Basel, Switzerland.
  • Martin and Louis are stellar additions to the LifeMine executive team and share in our vision to reinvent small molecule drug discovery through genomic search and retrieval from the biosphere, said Gregory Verdine, Ph.D., co-founder, president and chief executive officer of LifeMine.
  • Martin and Louis experience and expertise will only help further accelerate our efforts.

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022
People, CRKP, Group, World, Klebsiella pneumoniae, Health, KPC, Infection, HKEX, Prevalence, LLC, Hospital-acquired pneumonia, Commonwealth, Klebsiella, HAP, Republic, World Health Organization, Holding, Meropenem, Partnership, Menarini, Therapy, Patient, Cancer, Contributor License Agreement, Vaborbactam, Injection, Philippe Ciais, CRE, Toxic shock syndrome, License, Urinary tract infection, Marketing, Union, Cutis marmorata telangiectatica congenita, Mortality, Serine, Antibiotics, Pharmaceutical industry, Hospital, Meropenem/vaborbactam, Melinta Therapeutics

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaboremin China and bring better treatment options to patients with severe ailments.

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022
People, CRKP, Group, World, Klebsiella pneumoniae, Health, Minocycline, KPC, Infection, HKEX, Prevalence, LLC, Hospital-acquired pneumonia, Commonwealth, Klebsiella, HAP, World Health Organization, Holding, Republic, Meropenem, Partnership, Menarini, Therapy, Patient, Cancer, Contributor License Agreement, Vaborbactam, Injection, Philippe Ciais, CRE, Toxic shock syndrome, License, Urinary tract infection, Marketing, Union, Cutis marmorata telangiectatica congenita, Mortality, Multimedia, Serine, Antibiotics, Pharmaceutical industry, Hospital, Meropenem/vaborbactam, Melinta Therapeutics

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaborem in China and bring better treatment options to patients with severe ailments.

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Thursday, September 8, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Philippe Ciais, II, Morgan, Hilltop Holdings Inc., Multiplicity of infection, Fluticasone furoate/umeclidinium bromide/vilanterol, Angiotensin, GSK, Distributive shock, Investor relations, Infection, Conference, Nasdaq, Blood pressure, Multidrug-resistant bacteria, Acquisition, Septic, Pharmaceutical industry

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.

Key Points: 
  • Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.
  • Innoviva is a diversified holding company with a portfolio of royalties and innovative healthcare investments and assets.
  • Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA.
  • ANORO, RELVAR, BREO, TRELEGY and ELLIPTA are trademarks of the GSK group of companies.

Innoviva Completes Acquisition of La Jolla Pharmaceutical

Retrieved on: 
Monday, August 22, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Security (finance), Philippe Ciais, II, Securities Exchange Act of 1934, Tax, Nasdaq, Multiplicity of infection, Exercise, Fluticasone furoate/umeclidinium bromide/vilanterol, Angiotensin, GSK, Coronavirus, Result, Distributive shock, Physician, Septic, Infection, Data analysis, U.S. Securities and Exchange Commission, Hospital, Goal, Blood pressure, Communication, Financial condition report, Analysis, Private Securities Litigation Reform Act, Acquisition, Patient, Pharmaceutical industry, Risk management, Entasis

Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.

Key Points: 
  • Today, following the consummation of the tender offer, Innoviva successfully completed its acquisition of La Jolla, which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.
  • The acquisition of La Jolla strengthens our footprint in the hospital and infectious disease spaces by adding a robust portfolio of marketed products and an excellent team, said Pavel Raifeld, Chief Executive Officer of Innoviva.
  • All conditions of the offer were satisfied and Innoviva completed its acquisition of all issued and outstanding equity securities of La Jolla for the Offer Price.
  • As a result of the acquisition, La Jolla became a wholly-owned subsidiary of Innoviva and the companys common stock will be delisted from the Nasdaq Global Market.

Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan

Retrieved on: 
Thursday, August 11, 2022
Social conditions in Honduras, Gastrointestinal tract, Cholecystitis, Aerobic organism, NDA, Peritonitis, MDR, Daptomycin, Technology, Multiplicity of infection, Philippe Ciais, Cancer, Life, Critical care, Marketing, Patient, Review, Bronchopneumonia, Stomach, Appendicitis, Company, Infection, HKEX, Partnership, Tetracycline, Doctor of Philosophy, Degenerative disease, Perforation, News, TTY, Gram-positive bacteria, Solution, CMC, Diverticulitis, Medicine, Food, Terminology, Pharmaceutical industry, Vaccine, Colistin, Eravacycline, Mount Everest, MD

SHANGHAI, Aug. 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that the Taiwan Food and Drug Administration (TFDA) has accepted the submission of a New Drug Application (NDA) for Xerava™ (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI).

Key Points: 
  • In addition, the Company has entered into an exclusive partnership agreement with TTY Biopharm (TTY) for commercialization of Xerava in Taiwan.
  • It is not only being one of the top pharmaceutical companies in Taiwan, but also focuses on international marketing.
  • Under the partnership, which includes a 10-year term upon the launch of Xerava in Taiwan with possibility of extension, TTY will be responsible for all commercialization of the product in Taiwan.
  • Everest Medicines has built a portfolio of elevenpotentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development.

DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY

Retrieved on: 
Monday, August 1, 2022
IDSA, Philippe Ciais, Anesthesia, Infection, EU, Infectious Diseases Society of America, Ertapenem, Abscess, Distributive shock, ISIN, Remimazolam, Intra-abdominal infection, Angiotensin, Tetracycline, PA8, Royal commission, Eravacycline, Sepsis, Federal Joint Committee (Germany), Septic, Hypotension, Aachen, Product, Abdominal cavity, European Commission, European Medicines Agency, Frankfurt Stock Exchange, Patient, Health, Peritonitis, Multiplicity of infection, Meropenem, ICU, Critical care, Dietary supplement, Pharmaceutical industry, European

In April 2022, the Federal Joint Committee (G-BA) voted in favour of PAIONs application for eravacycline as a reserve antibiotic.

Key Points: 
  • In April 2022, the Federal Joint Committee (G-BA) voted in favour of PAIONs application for eravacycline as a reserve antibiotic.
  • Eravacycline is approved by the European Commission and the UK Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI) in adults.
  • Eravacycline is an important new treatment option for patients suffering from serious intra-abdominal infections.
  • Eravacycline is an antibiotic used to treat complicated intra-abdominal infections (cIAI) in adults.